Amgen Inc AMGN

Revenue Intelligence Report • 70 quarters of SEC filing data • Updated 2026-03-06

Amgen Inc's revenue is primarily driven by its strategic investments in selling, general, and administrative (SG&A) expenses, with each dollar spent generating an impressive $11.11 in long-run revenue. Despite a holdout test revealing a 6.1% prediction error, the company's model demonstrates a solid accuracy of 2.5% MAPE, indicating reliable forecasting capabilities. For the upcoming fiscal year, Amgen is projecting a revenue of $36 billion, reflecting a slight decline of 1.2% year-over-year. Investors should consider the company's strong ROI on SG&A spending as a key factor in its revenue generation potential, while remaining mindful of the anticipated revenue dip.

Next FY Revenue
$36.33B
-1.2% YoY
SG&A Multiplier
$11.11 per $1
Model Accuracy
2.5% MAPE
Holdout validation: The model predicted $9B vs the actual $10B — an error of 6.1%.
Note: Amgen Inc does not report R&D expenses separately. This analysis uses SG&A spending only.

Revenue Forecast

AMGN Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $9B $10B $9B – $10B +2.0% ✗ Outside range
Q2 2026 $9B $8B – $9B +10.3%
Q3 2026 $9B $9B – $10B -0.1%
Q4 2026 $9B $8B – $10B -4.0%
Q1 2027 $9B $8B – $10B -8.8%

How Spending Drives Revenue

AMGN Spending Timing
Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch